Via E-Mail
August 19, 2021

To: **The Office of the Vermont Attorney General**
AGO.highcostprescriptiondrugs@vermont.gov

Notification of a New Prescription Drug Pursuant to 18 V.S.A. § 4637(b)

On August 6, 2021, the Food & Drug Administration (FDA) approved NEXVIAZYME™ (avalglucosidase alfa-ngpt) as a long-term enzyme replacement therapy (ERT) for the treatment of patients one year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency). Genzyme Corporation (referred to herein as "Genzyme"), manufactures NEXVIAZYME™, which has a wholesale acquisition cost (WAC) that exceeds the threshold set for a specialty drug under the Medicare Part D program. Therefore, pursuant to 18 V.S.A. § 4637(b), Genzyme hereby provides written notice to the Office of the Attorney General that it introduced NEXVIAZYME™ to the commercial market on August 17, 2021. We have provided information about the new prescription drug in the grid below.

Manufacturer	Genzyme Corporation
Product Name	NEXVIAZYME™ (avalglucosidase alfa-ngpt)
NDC	58468-0426-01
Date of Introduction to Market	August 17, 2021

In providing this notice, Sanofi expressly reserves any and all rights or claims it may have with respect to 18 V.S.A. § 4637, the company's interpretation thereof, or the statute's application to Sanofi, Genzyme Corporation, or any other entity affiliated with or otherwise under the control of Sanofi.

Sincerely,

Phillip Ridolfi
Head, Sales Support Operations